BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 15851522)

  • 1. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
    Looney RJ
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
    Kazkaz H; Isenberg D
    Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the role of rituximab in the treatment of rheumatoid arthritis?
    Atzeni F; Doria A; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell-targeted therapy in diseases other than rheumatoid arthritis.
    Looney RJ
    J Rheumatol Suppl; 2005 Feb; 73():25-8; discussion 29-30. PubMed ID: 15693113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rituximab in systemic lupus erythematosus. Part I. Theoretical basis].
    Kardynał A; Rudnicka L
    Pol Merkur Lekarski; 2010 Aug; 29(170):131-4. PubMed ID: 20842829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CD20 antibody for the treatment of systemic autoimmune diseases].
    Tanaka Y
    Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.
    Silverman GJ; Weisman S
    Arthritis Rheum; 2003 Jun; 48(6):1484-92. PubMed ID: 12794814
    [No Abstract]   [Full Text] [Related]  

  • 13. [Rituximab in systemic lupus erythematosus. Part II: review of clinical experience].
    Kardynał A; Rudnicka L
    Pol Merkur Lekarski; 2010 Aug; 29(170):135-40. PubMed ID: 20842830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
    Taylor RP; Lindorfer MA
    Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cells in rheumatoid arthritis: from hypothesis to the clinic.
    Keystone EC
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cells move to centre stage: novel opportunities for autoimmune disease treatment.
    Browning JL
    Nat Rev Drug Discov; 2006 Jul; 5(7):564-76. PubMed ID: 16816838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
    Dörner T
    J Rheumatol Suppl; 2006 May; 77():3-11. PubMed ID: 16652439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
    Perosa F; Prete M; Racanelli V; Dammacco F
    J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
    Levesque MC; St Clair EW
    J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.